Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prana eyes Phase III for lead asset on Huntington's data

This article was originally published in Scrip

Executive Summary

Phase II data for Prana Biotechnology's investigational therapy PBT2 show that it is safe and tolerable, with enough suggestion of clinical efficacy in early to mid-stage Huntington's disease for the company to take it into Phase III. Shares in the firm were up by as much as 24% to $9.10 in trading on Nasdaq on the morning of 18 February.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC024466

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel